These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10720316)

  • 1. Mechanism-based target identification and drug discovery in cancer research.
    Gibbs JB
    Science; 2000 Mar; 287(5460):1969-73. PubMed ID: 10720316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
    Hidalgo M
    Adv Exp Med Biol; 2008; 610():128-43. PubMed ID: 18593020
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in cancer drug discovery - a British association for cancer research meeting.
    Westwell AD
    IDrugs; 2008 Nov; 11(11):783-6. PubMed ID: 18988118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 5. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics.
    Kayser KJ; Glenn MP; Sebti SM; Cheng JQ; Hamilton AD
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2068-73. PubMed ID: 17276059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors.
    Asoh K; Kohchi M; Hyoudoh I; Ohtsuka T; Masubuchi M; Kawasaki K; Ebiike H; Shiratori Y; Fukami TA; Kondoh O; Tsukaguchi T; Ishii N; Aoki Y; Shimma N; Sakaitani M
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1753-7. PubMed ID: 19217288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
    Spinello A; Martini S; Berti F; Pennati M; Pavlin M; Sgrignani J; Grazioso G; Colombo G; Zaffaroni N; Magistrato A
    Eur J Med Chem; 2019 Apr; 168():253-262. PubMed ID: 30822713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
    Lombardi P
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target selection issues in drug discovery and development.
    Sausville EA
    J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
    Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
    Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges.
    Workman P
    Curr Cancer Drug Targets; 2001 May; 1(1):33-47. PubMed ID: 12188890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole after tamoxifen for breast cancer--what is the price of success?
    Bryant J; Wolmark N
    N Engl J Med; 2003 Nov; 349(19):1855-7. PubMed ID: 14551339
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002.
    Yasui W; Nishiyama M; Tsuruo T; Tahara E
    Cancer Sci; 2003 Feb; 94(2):221-3. PubMed ID: 12708501
    [No Abstract]   [Full Text] [Related]  

  • 18. An inhibitor of glutathione S-transferase omega 1 that selectively targets apoptotic cells.
    Pace NJ; Pimental DR; Weerapana E
    Angew Chem Int Ed Engl; 2012 Aug; 51(33):8365-8. PubMed ID: 22777685
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of natural products on developing new anti-cancer agents.
    Cragg GM; Grothaus PG; Newman DJ
    Chem Rev; 2009 Jul; 109(7):3012-43. PubMed ID: 19422222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.